

Endophthalmitis

[View the current Endophthalmitis InDepth page on BioPortfolio.com](#) ([PDF](#))

(<http://www.bioportfolio.com/indepth/Endophthalmitis.html>) - Regularly Updated.

Endophthalmitis is an inflammation of the internal coats of the eye. It is a dreaded complication of all intraocular surgeries, particularly cataract surgery, with possible loss of vision and the eye itself. Infectious etiology is the most common and various bacteria and fungi have been isolated as the cause of the endophthalmitis. Other causes include penetrating trauma and retained intraocular foreign bodies. ([From the Wikipedia article Endophthalmitis](#).)

Recent Publications on Endophthalmitis:



- [Staphylococcus aureus Endophthalmitis: Antibiotic Susceptibilities, Methicillin Resistance, and Clinical Outcomes.](#)
*PURPOSE: To investigate the antibiotic susceptibility and clinical...*21st November, 2009
Department of Ophthalmology, Bascom Palmer Eye Institute, University of- Am J Ophthalmol. 2009 Nov 17. ([DOI Direct Link](#))
- [Endophthalmitis caused by Pseudomonas aeruginosa after phakic posterior chamber intraocular lens implantation to correct high myopia.](#)
*PURPOSE: To investigate the antibiotic susceptibility and clinical...*21st November, 2009
Department of Ophthalmology, Graduate School of Medicine, Pusan National- Acta Ophthalmol. 2009 Nov 19. ([DOI Direct Link](#))
- [Enterococcus casseliflavus endophthalmitis associated with a horse tail injury.](#)
*Of the filtering procedures employed, trabeculectomy is the one most...*18th November, 2009
- Arch Ophthalmol. 2009 Nov;127(11):1551-2. ([DOI Direct Link](#))
- [Traumatic endophthalmitis caused by Staphylococcus gallinarum.](#)
*Herein, we describe what is believed to be the first case of traumatic...*17th November, 2009
L.V. Prasad Eye Institute.- J Med Microbiol. 2009 Nov 12. ([DOI Direct Link](#))
- [\[Postoperative complications and management of filtration surgery.\]](#)
*Of the filtering procedures employed, trabeculectomy is the one most...*13th November, 2009
Klinik fur Augenheilkunde, Universitatsklinikum des Saarlandes, Kirrberger- Ophthalmologe. 2009 Nov 11. ([DOI Direct Link](#))
- [Trabeculectomy with OloGen versus trabeculectomy for the treatment of glaucoma: a pilot study.](#)
*Abstract. Purpose: To present the preliminary results of our study...*11th November, 2009
Department of Ophthalmology, University of Athens, Greece.- Acta Ophthalmol. 2009 Nov 7. ([DOI Direct Link](#))
- [Conjunctival and corneal findings in bleb-associated endophthalmitis: an in vivo confocal microscopy study.](#)
*Abstract. Purpose: To report the conjunctival and corneal findings in...*11th November, 2009
Department of Medicine and Ageing Science, Ophthalmic Clinic, University- Acta Ophthalmol. 2009

- Nov 7. ([DOI Direct Link](#))
- [\[Endophthalmitis or TASS--case report\]](#)
*We present the case of a 65-years-old female with a history of...*11th November, 2009
 Szent Rokus- Ophthalmologia. 2009;53(3):90-3.
 - [Re: Fungal endophthalmitis: fourteen years' experience from a center in India.](#)
*We present the case of a 65-years-old female with a history of...*10th November, 2009
 - Retina. 2009 Nov-Dec;29(10):1548; author reply 1548-9. ([DOI Direct Link](#))
 - [Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months.](#)
*PURPOSE: The purpose of this study was to compare the injection burden,...*10th November, 2009
 Instituto de Cirugia Ocular, San Jose, Costa Rica.- Retina. 2009 Nov-Dec;29(10):1396-403. ([DOI Direct Link](#))
 - [Postoperative infection in penetrating versus non-penetrating glaucoma surgery.](#)
*AIM: To review the literature for the incidence and risk factors for...*10th November, 2009
 Aberdeen Royal Infirmary, United Kingdom;- Br J Ophthalmol. 2009 Nov 5. ([DOI Direct Link](#))
 - [\[Clinical characteristics and risk factors of glaucoma filtering bleb infections\]](#)
*PURPOSE: To obtain useful information for the appropriate prevention and...*4th November, 2009
 Department of Ophthalmology, Gifu University Graduate School of Medicine,- Nippon Ganka Gakkai Zasshi. 2009 Oct;113(10):951-63.
 - [Endophthalmitis after vitrectomy and vitrectomy combined with phacoemulsification: incidence and visual outcomes.](#)
*Purpose. To study the incidence of endophthalmitis after vitrectomy and...*3rd November, 2009
 Al Bahar Ophthalmology Center, Kuwait City - Kuwait.- Eur J Ophthalmol. 2009 Nov-Dec;19(6):1045-50.
 - [Risk factors for culture-positive endophthalmitis after repair of open globe injuries.](#)
*purpose. To identify risk factors for the development of culture-positive...*3rd November, 2009
 Department of Ophthalmology, College of Medicine, King Saud University,- Eur J Ophthalmol. 2009 Aug 5.
 - [Periorbital cellulitis caused by Bacillus thuringiensis.](#)
*Purpose. Periorbital cellulitis is an inflammation of the lids and...*3rd November, 2009
 Department of Pediatrics, Yuzuncu Yil University School of Medicine, Van -- Eur J Ophthalmol. 2009 Jul 24.

BioNews Results for Endophthalmitis

- [Staphylococcus aureus Endophthalmitis: Antibiotic Susceptibilities, Methicillin Resistance, and Clinical Outcomes](#)
MDLinx: Nov 19 2009 11:00AM Matching: endophthalmitis
- [An Outbreak of Post-Cataract Surgery Endophthalmitis Caused by Pseudomonas aeruginosa](#)
MDLinx: Oct 22 2009 12:23PM Matching: endophthalmitis
- [Journal Club](#)
Retinal Physician: Oct 18 2009 11:10AM Matching: endophthalmitis
- [Endophthalmitis following Open Globe Injury](#)
British Journal of Ophthalmology: Oct 14 2009 11:33PM Matching: endophthalmitis
- [Study data from Rajpal and colleagues update understanding of endophthalmitis](#)
Pharmacy Choice: Oct 14 2009 11:19AM Matching: endophthalmitis
- [Successful Prevention of Bacterial Endophthalmitis in Eyes with the Boston Keratoprosthesis](#)
MDLinx: Oct 12 2009 1:04PM Matching: endophthalmitis



Endophthalmitis Patents:

- 7384648- [Implant device with a retinoid for improved biocompatibility](#)
- 7439372- [Therapeutic compounds](#)
- 7452684- [Collagen XXII, a novel human collagen and uses thereof](#)
- 7459165- [Polypeptides of Pseudomonas aeruginosa](#)
- 7468360- [Therapeutic amides and related compounds](#)
- 7473762- [Proteins and polypeptides from coagulase-negative staphylococci](#)
- 7479481- [Treatment of ocular diseases and disorders using lantibiotic compositions](#)
- 7482360- [Fused tetracyclic mGluR1 antagonists as therapeutic agents](#)
- 7485648- [mGluR1 antagonists as therapeutic agents](#)
- 7491390- [Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders](#)
- 7491844- [Therapeutic cyclopentane derivatives](#)
- 7432369- [Pyridyl-substituted porphyrin compounds and methods of use thereof](#)
- 7427685- [Therapeutic substituted cyclopentanes](#)
- 7419994- [4-\(substituted cycloalkylmethyl\) imidazole-2-thiones, 4-\(substituted cycloalkenylmethyl\) imidazole-2- thiones, 4-\(substituted cycloalkylmethyl\) imidazol-2-ones and 4-\(substituted cyloalkenylmethyl\) imidazol-2-ones and related compounds](#)
- 7390829- [Alpha-2 adrenergic agonists](#)
- 7393955- [Isoquinoline derivatives and methods of use thereof](#)
- 7396659- [Inhibitors of nitric oxide synthase to treat type 1 diabetes](#)
- 7396849- [4-\(Condensed cyclicmethyl\)-imidazole-2-thiones acting as .alpha..sub.2 adrenergic agonists](#)
- 7399868- [4-\(Heteroaryl-methyl and substituted heteroaryl-methyl\)-imidazole-2-thiones acting as alpha2 adrenergic agonists](#)
- 7405226- [Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses](#)
- 7410642- [Assays and therapies for latent viral infection](#)
- 7414062- [Triazaspiro compounds useful for treating or preventing pain](#)
- 7419666- [Treatment of ocular disorders](#)
- 7419672- [Genes and proteins, and their use](#)
- 7501133- [Light-activated adhesive composite, system, and methods of use thereof](#)
- 7504494- [Multiplex PCR assay](#)
- 7572812- [Therapeutic agents useful for treating pain](#)
- 7576130- [Dihydroxyl compounds and compositions for cholesterol management and related uses](#)
- 7582604- [Template-fixed peptidomimetics with antibacterial activity](#)
- 7582635- [Therapeutic agents useful for treating pain](#)
- 7585895- [Therapeutic substituted cyclopentanes](#)
- 7589057- [Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems](#)
- 7592011- [Genes and proteins, and their use](#)
- 7592341- [Peptide-enhanced corneal drug delivery](#)
- 7598259- [mGluR1 antagonists as therapeutic agents](#)
- 7601335- [Pretreatment of a biological sample from an autoimmune disease subject](#)
- 7572781- [Prodrugs for use as ophthalmic agents](#)
- 7569584- [4-\(2-methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl\)-1,3-dihydro-imidazole-- 2-thione as specific alpha.sub.2b agonist and methods of using the same](#)

- 7563255- [Implantable drug delivery device and use thereof](#)
- 7513893- [Device and method for treatment of eyelid diseases](#)
- 7517864- [RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid \(siNA\)](#)
- 7524843- [Fab I inhibitors](#)
- 7534779- [Quinol compound and pharmaceutical composition](#)
- 7534878- [Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases](#)
- 7547435- [Pharmacological vitreolysis](#)
- 7550497- [Phosphoramidate derivatives](#)
- 7553486- [Anti-VEGF treatment for radiation-induced vasculopathy](#)
- 7557125- [Fab I inhibitors](#)
- 7557128- [Optically active isomers of ketotifen and therapeutically active metabolites thereof](#)
- 7611714- [Methods and compositions for immunizing against Pseudomonas infection](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

